A novel immunity based test for early diagnosis of Lyme disease
The main objective of this ID-Lyme project was to push to the market a novel test, the Ixodes kit, for the early detection of Lyme Borreliosis (LB), also known as Lyme disease. LB can usually be treated using cost-effective antibi...
The main objective of this ID-Lyme project was to push to the market a novel test, the Ixodes kit, for the early detection of Lyme Borreliosis (LB), also known as Lyme disease. LB can usually be treated using cost-effective antibiotics at an early stage of disease. Unfortunately, standard laboratory testing is often unable to give a clear diagnosis whether a patient is infected or not. This can result in the true infection remaining untreated. This is a significant healthcare concern because of the disabling effects and the much costlier and more challenging treatment of progressive disease. This project was to deliver to the market the first point-of-care diagnostic test that can identify LB infections in the early stage prior to the onset of symptoms thereby improving LB management and patient health outcomes as well as reducing LB-related healthcare costs. When successful, the project would have significant impact on EU healthcare and society, as currently over 2.6 million tests are performed in the EU each year on people suspected of LB infection.
With support of the Fast Track to Innovation program by Horizon2020, a dedicated consortium of in vitro diagnostic assay developers (Innatoss Laboratories), production specialists (NPK, Diarect) and clinical experts (Medical University of Vienna) will finalize the kit design, upscale production, and test the product under real-life conditions to prepare the kit for EU-wide market introduction and implementation. The Ixodes kit will result in:
1. early and effective treatment of patients;
2. quality of life of patients; and
3. large direct and indirect cost reductions on a EU-wide level.
Unfortunately, the discriminatory power of the Ixodes test was insufficient to progress to the intended performance study. Instead, the WOLF device that has been developed as part of the Ixodes kit will aim for development of kit components as stand-alone diagnostic tools that will have broad application for whole blood tests.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.